hockey. >> brilliant. >> you know what else is brilliant? gold. i think it's going up tomorrow. gdx. >> i'm melissa lee. thanks, so much for watching. see you tomorrow at 5:00. meantime, don't go anywhere. "mad money" with my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere and i promise to help you find it. "mad money" starts now. hey, i'm cramer, welcome to "mad mone money", welcome to cramerica. most people want to make friends, i just want to make you money. my job is not just to train you, but to educate and teach you. few things are harder to pull off than a corporate turn around.

even when it looks like a company has already made a turn around, you need to stay close to them in order to know whether managementceed or fail. i mention this because when we're dealing with a gigantic company, a turn around or a lack thereof can affect the entire stock market. that's buy the dow jones fell 143 points. the nasdaq actually advanc advanced .23%. what caused the dow to get clocked? this was all about ibm's busted turn around story. the failu yes, 20 straight quarters of

declining sales. because of the way the dow is weighted, the downward tug of ibm stock, shaved more than 57 points off the dow, and i have been procuring some successful turn arounds, wall martimartwal mcdonald's and coca-cola. ibm is in the midst of an incredibly difficult turp around. while at the same time expanding into faster growing new tech areas that attract a different and morrow bust group of investors. ibm wants to become known as the company that uses watson's

platform. watson wants to be viewed as a place to mine data and put it to use, and the more data the better. the problem is that ibm needs to keep signing up new customers for all the rest of its businesses at a pace that's enough to not drag down the whole company's earnings with it. that's where ibm failed in their turn around. now wall street has suddenly turned incredibly negative on ibm and it's ceo for the big revenue. some people are saying that the company only manages to make it's earnings numbers by manufacturing lots of one-time only gains, like licensing intellectual property. i think ibm is totally justified in what it's doing. and if they had signed up more business, if they had actually made those sales, then everyone

would have been happy. they didn't, i know that's a big deal, i'm not excusing them. but i'm not sure that cfo martin -- that said, let's look at the situation, ibm's a great american company, but it's clearly taken too long to make this transition, granted turning around such a large company, they have 86,000 employees at ibm. you might argue it's harder to turn around an aircraft carrier, but i think ibm is harder because an aircraft carrier has steering. a partnership with sales force stock that continues to produce results in the second half of this year and the cfo's promise, promise that the unsigned business will be signed pretty soon. put it all together, and i do not want to sell ibm stock

around $160, i would rather buy it. when successful turn arounds do occur, they can yield spectacular gains for investors. consider the three other dow stocks that i think are making big come backs, coca-cola, mcdonald's and walmart. these companies have been gaining adherence on wall street because their managements have positioned them to deliver earnings that could be far better than expected, both in the second half of this year and in 2018. i have been supporting the turn around at coca-cola, ever since the ceo said that they would be -- hand this business off to his successor. today's credit sweeps are an important but overlooked piece of research, upgreaded the stoc from hold to buy to the new coca-cola, which analysts say is

smarter, leaner and more aligned, and now it can focus on what it does best. credit suite tells us that growth is the new frontier. and because the company refranchised it's bottlers, a really slow growing part of the beverage food sales, credit suite says this is the core of what you need to be thinking about. the core coke will deliver growth not seen for at least the last five years. i trust the credit suite report, i trust coca-cola. the successor will be coming in hot. granted i still love pepsico owned by my travel trust, because . i believe the transformation will send its stock higher.

given the strength of ibm's strength of both the ibm balance sheet and the coca-cola balance sheet, i think it's a lot better owning a 2.2% yield in the treasury is better. how about mcdonald's. close watchers to the show know that i have been a huge fan of steve esther brooke, it closed at over $102. how did mcdonald's get there? eithast easterbrook, the food chain's got to catch up to it. it's interesting a lot of cost saving customer friendly technology, and of course rolling out all day breakfast. i find this man inspirational. these franchisees are more

amenable to making the stores cleaner, brighter, more competitive in an increasingly dog eat dog competitive world. mcdonald's balance sheet is a thing of wonder and the company can take on all comers. finally let's talk walmart, walmart stock has been going up pretty steadily of late, up .07% for the year, why? because the company is beginning to reap the seeds that the ceo has sewn. when mcmillan lowered expectations all at once and talked about spending more in the stores, more on e commerce and on wages in order to make the business more competitive, but walmart stock is pretty much to where it was when mcmillan took the helm three years ago.

they're paying higher wages, which saves the company a ton. e commerce efforts now include free two-day shipping a discounted price for 10,000 different items if you pick them up at the store. and then here again, 2.75% yield, being paved away, all three of these companies share that key attribute of having enough money to pull off their turn arounds. ibm, i'm disappointed yet again. but a year ago when i began to have faith in the turn, ibm stock is at $144, now it's at $161, i think turn arounds take time, so hold on to your ibm, they might get it done. the fact that ibm's turn hasn't

happened since 2012, makes me feel that if they don't get it right this year, it might be the year warren buffett will finally bring in the -- >> caller: with the earnings coming out on the 27th, if it's a buy, sell or a hold. >> i think mgm is going to be delivering. the national harbor casino, why i do mention it? because it hurt the earning last quarter, it won't do so this quarter, at $28 i want to buy mgm. jack in georgia, jack. >> caller: hey, jim, this is jack, i had a couple of questions for you about t-mobile stock. >> sure. >> caller: i know t-mobile

bought $8 million from -- what are the top three telecommunications stock. >> t-mobile has been my favorite in the group, and it's been that way for a long time. i think john ledger is doing the real thing, even though i have to tell you, sometimes he has that guerrilla marketing, i would say t-mobile first, then i would go with verizon, because i like-year-old, then i would go with sprint because i still believe in that turn, and then att which got a couple of number cuts that do concern me. but t-mobile, all-time high today. correct, going higher. turn arounds are vital for any company to survive and thrive. we have seen the success in coca-cola, walmart and mcdona mcdonald's, but ibm, they have to get it right and get it right this year.

i'm tackling the technicals in some of the hottest stocks. do you have a fear of rejection, so do the drug stocks, just look at ely lily, the drug stock, after the fda failed to approve their arthritis drug. and it's the fastest growing medical robotics company, i'm talking with the ceo, don't miss my exclusive with mazer robotics, stick with cramer.

with e*trade you see things your way. ♪ ♪ you have access to the right information at the right moment. ♪ ♪ and when you filter out the noise, it's easy to turn your vision into action. ♪ ♪ it's your trade. e*trade. start trading today at etrade.com

but we've got the get tdigital tools to help. now with xfinity's my account, you can figure things out easily, so you won't even have to call us. change your wifi password to something you can actually remember, instantly. add that premium channel, and watch the show everyone's talking about, tonight. and the bill you need to pay? do it in seconds. because we should fit into your life, not the other way around. go to xfinity.com/myaccount last night, uber cramer fake glamour search, that semiconductor equipment maker reported a fabulous quarter. it shot up into the stratosphere today.

when companies like glam are doing well, it's good news for the whole semiconductor complex. why? they need to boost their output when they need to meet rising demand. from quarter, the semiconductor bull market, even though the market looked bad is still going strong. and that's why tonight we have to go off the charts and take a closer look at semis. let's take a look at sue smith, she's a terrific technician, she also happens to be the co-founder of explosives opti options.net. even after experiencing a mild pull back this month, sue says -- for the first quarter, the vaneck vectors semi, tradeses under smh, it was up over 5% in the same period including dividends. when the smh pulled back earlier

this month, it found a powerful core of support in his long-term trend line, and for the last few days, it has been bouncing back pretty hard. that being said, we much prefer to do some home work rather than picking winners. when it comes to the semis, there are three particular names that smith is really keying on. microchip technology, which makes microchips for all kinds of devices, and then advanced microdevices, now very controversial amd, it was the best performing semi of 2016. this is one of smith's favorites in the space, even though it's more of a low tech semi play than a high one.

with the latest leg of this epic move starting at the end of december, really, really powerful. what you're looking at by the way when you see this, it's just a straight up situation and no one talks about this chart, no one talk about the stock. and one of the reasons i always say it's worth looking at the charts, is that these picto graphs can show you what the stock is doing. and in the case of microchip, smith says we're dealing with a stock that's -- given this trajectory, even if we haven't talked about it that much on the show. beyond that, smith points out that this stock recently had a successful test of it's 50-day moving averages at about 72 and change. meanwhile the oscillator, this is a momentum indicator, it's

flashing a buy signal right here, and that usually means the stock is going to move higher. plus the moving average convergence which we call the macd indicator just made a bullish crossover, and that's very important, that's where the black line crosses above the red, this is one of the reliably positive indicators out there. if reliable technology can clear only a few cents above where the stocks are currently trading, then smith believes that it can make its way to 86 in the not too distant future, if the quarter is good, and that wouldn't shock me, because business is strong, and that could be the catalyst that gets it up there. and how about a real controversial one, micron, here's a stock that spent last year roaring higher, and if smith is right, it's got even

more room to run. they make commodity products, e d-rams, flash model ships, eventually micron's shock will go bust. but it had a while before this move runs out of juice. smith predicts a pattern of higher highs, and lower lows. and that gives the -- that gives the stock an astonishing more than 50% gain just since the election. now micron already reported at the end of march, and while the stock surged higher on very strong results, it subsequently pulled back from just over 29 to 27. in the last few sessions, micron has begun to bounce and smith sees a number of signs that suggest this is rally is here. first the oscillator is turning up from some deeply sold levels.

that's a classic symbol that it's time to buy. you can see that turnup, and that's what happens when the black line crosses, plus the williams r oscillator, created by that legendary commodities fray trader, seems poised to move higher off a very major sold level, just like micron in december, january and deb february, three oversolds, makes three big moves. smith thinks t s ths the patter micron stock is like last december when the moving average was trending up. then we got a major move. perhaps best of all, smith reports a micron floor of $75.84, about a buck and a half below where this stock is

currently smooth sailing. a lot of people are in micron, but not as many as in the next stock we're going to be talking about, the chart of advanced microdevices, a md. i know this has got a lot of people talking. after nearly quadrupling last year, this stock has been trading sideways since february, it's very frustrating to people, i know that. the reason in 2016, amd, it's fellow graphics chipmakers -- they were some of the only semiconductors whose growth could be relied on. because apple and samsung both have new hot smart phones, the cell phone oriented chipmakers have gotten their mojo back so the amd stock has got more money from institutional investors. however smith likes what she see here's. it's selling currently on lower volume. that's key, see the volume in the cell, the volume's been

dying down, that is good, that means that traders may be les involved. meanwhile it's in deeply oversold territory and turning up. smith says is a terrific buy signal. she says that it's the high of its 50-day moving average. but here's the bottom line, thanks to lam research, questwe that semiconductor companies are on fire. microchip technology, micron and amd are all worth buying. watch more "mad money," and you'll see my insight into the tumble for ely lily after the fda dealt a blow to their

arthritis medication. and i get it, you want to prep for whatever could happen if this contentious french election that we keep hearing about in weekend, i'll tell you why all that worry may be exactly the wrong move. so stick with cramer. why pause a spontaneous moment? cialis for daily use treats ed and the urinary symptoms of bph. tell your doctor about your medicines,

and ask if your heart is healthy enough for sex. do not take cialis if you take nitrates for chest pain, or adempas® for pulmonary hypertension, as this may cause an unsafe drop in blood pressure. do not drink alcohol in excess. to avoid long-term injury, get medical help right away for an erection lasting more than four hours. if you have a sudden decrease or loss of hearing or vision, or an allergic reaction, stop taking cialis and get medical help right away. ask your doctor about cialis. there goes my sensitive bladder. sound familiar? then you'll love this. always discreet. incredible protection...

in a pad this thin. i didn't think it would work. but the super absorbent core turns liquid to gel for incredible protection. so i know i'm wearing it... but no one else will. always discreet. i've discovered incredible... bladder leak underwear that hugs every curve. can't tell i'm wearing it... can you? always discreet underwear. for bladder leaks. i always say it's better to be lucky than good, but no one can be lucky all the time. last week i recommended incyte. a few days later, while we were enjoying our long weekend here, the fda rejected one of ely li y

lily's arthritis drugs. that's when the stock got slammed. ely lily got hit too, going from 85 down to 82. went as low as 80 today. so what do we do now? the response from the fda that the drug receive more trials before being approved. the drug had already been approved in europe, and it was supposed to be a blockbuster drug, but now it will take longer for it to hit the market here in the u.s., in fact it might never happen. it all begs the question, what should we do with the insight in ely lily after this major stumbling block. it's a good question actually. the main reason i did like the stock and still do was it's terrific anti-cancer pipeline, obviously it's a much smaller piece of the pie, and lily still boasts some fabulous franchises and excellent pipelines.

so what exactly do we make of this not so hot regulatory decision? have these stocks hit a speed bump? or did they just crash into a retaining wall at 90 miles an hour. let's start with incyte. for those of you who don't know, let me give you some background so you can understand what the fda's decision means to the story. until recently incyte's stock had been hot. the reason? incyte is mainly a play in one of the sexiest sectors in biotech, jackify has fda approval to treat bone cancer. because of its mechanism of action, jackify is also in clinical trials as a treatment for a variety of anti-immune systems, where you get an organ trance plan. and the donor's white blood cells start attacking your body. this growth has been a big part

of the incyte story. then there's a pipeline. incyte's working on a bunch of exciting drugs, including the rheumatoid arthritis drug. but the company's lead pipeline asset is cancer immunotherapy drug that works in concert with some of the leading anti-cancer drugs on the market. bristol myers is omdivo. but bristol myers has a couple early cancer drugs yet to be approved. yesterday's fda announcement was a very big deal for incyte, i'm not playing it down. specifically the fda said they couldn't approve the drug in it's current form and they need additional data to determine which doses are appropriate. and while incyte's management said they remain confident that the rheumatoid arthritis drug will ultimately be approved,

they also covered the stock are also less sanguine, again it really caught people by surprise, because incyte had already gotten that approval in europe and normally that's a really good indicator that the drug will be approved here. you can watch testimony from doctors about why this thing is so socipecial. but here is the issue, incyte's stock has already dropped 10% on this news. holding this drug back for two years will definitely affect the company's earnings. but barrett is much more of a supporting player inside of incyte's broader pich line. i think there's some potentially broader catalysts that can take the stock higher. this is a powerful reminder, though, that playing fda roulette is always risky, but if you liked incite's story before

the anti-cancer drugs, you should still like it. how about ely lily? while lily stocks fell 4% on monday. right after the announcement, littly put out some earnings guidance. if barrett was going to hit 107 billion in peak sales, losing this drug should indeed have knocked 4 bucks off of lily's share price, according to analysts that did a lot of work on it. sure enough the stock is already down 5 bucks, i think to assume they make no money on this is going a bit too far. i do think the fda will ultimately relent, which means even shaving off the 4 bucks, this is all a side show compared to ely lily has going for it.

we know that limbally has a gigantic diabetes business, the company's new psoriasis drug. there's a big american society of clinical oncology meeting, the key with a big pharma stock like limbally, one drug doesn't matter that much. that's why i like lily at these levels. the company reports next week, and, you know what? if you can get into any additional weakness going into the quarter, i think you'll be pleasantly surprised at ely lily's stock, here's the bottom line, i obviously like others was surprised by the fda's negative decision to reject ely

li lily's arthritis drug. at these levels, i think these stocks are worth buying, they have been overly punished. littlely is a longer term investment. you might get a chance to buy some incyte even lower, once the company offers the secondary offering that many people are expecting that has yet to occur. let's go to eddie in california. eddie. >> caller: hi, jim, i'm a big fan of yours. can you tell me of nktr? >> nekter therapeutics. i'll tell you highway i felt about it. a little jarred by what happened at incyte, got to statake stock that and pull back on nikter.

we got to joe in connecticut. >> caller: i have a question about amgen, i have had the stock for a number of years, but they have some things in the pipeline. what do you say, buy, sell, hold? >> it's got huge assets overseas, a 2.58% yield, and i have been doing a monster amount of work on repatha which is the anti-cholesterol drug. i am still studying this, more work to do, but i will be back. the fda's response to incyte sure came out of left field. i think incyte and it's partner ely lily are still worth buying, lily at 80, i like it. much more "mad money" ahead, last we're going to introduce you to a medical device company,

mazor. mazor robotics, who says this isn't the most interactive show on television? we will always have paris, right? well, not if you want to be a successful investor. i'll explain. so stick with cramer. your insurance company

won't replace the full value of your totaled new car. the guy says you picked the wrong insurance plan. no, i picked the wrong insurance company. with liberty mutual new car replacement™, you won't have to worry about replacing your car because you'll get the full value back including depreciation. switch and you could save $509 on auto insurance. call for a free quote today. liberty stands with you™. liberty mutual insurance.

a used car,

last week i told you about this mazer robotics. here's a company that's kind of a smaller more speculative company which by the way rallied. major robotic systems help doctors do a better job of performing spinal surgery. mazor's stock jumped last week after getting approval for its software, and the stock just keeps climbing, like i told you last week, i don't like to chase, i bet this one still has more room to run, why? because it's still in the early innings, which could be a major close to your story. don't take it from me, he's the

ceo of mazor robotics. >> thank you for having me on the show. >> it's great to see you, you've got three pillars to your business model, i want you to share them with your viewers because it's such a great way to make money. >> thank you. i'll bids con sirs on the offer of the surgical robotic spichbl surgery, we sell a new product that we just launched a few months ago and our business model consists as you mentioned on three main pillars, we sell the robot themselves, and that's a capital unit, that we're selling at the list price of about 1.1, over $1 million per unit, we sell the disposable. that's per case, and we also charge for the service, all these together are a

comprehensive business model, and because of their revenues play a significant role in our business model. >> it is clear from the data that there are outcomes from the use of mazor robotics that are superior to just plain old surgery by doctors, can you explain what the outcomes are and how much better it is than the current system? >> yeah, actually, we over the years, we invested a lot in clinical studies and validating the clinical technology. and mazor is very much focused on the patient themselves. and in many of these studies surgeons tried to look at the results, okay, of spine surgeries without using the mazor older renaissance and older technologies versus surgery where is they use our technology. the results are outstanding. i can tell you that in recent

studies, they found out that the reduction in complications and the reduction in revision surgeries is sometimes up to six times less complication and ten times less revision surgeries when the new technology was used in these surgeries, and that's a blessing and it's a privilege to be involved in such technology. >> i think it's seemingly a privilege to have it in the hospitals. in one of your presentations, i see we are in new jersey, and new jersey's is the only hospital with robotic spine surgery, uconn health has it. has this become a drawing point? an actual attraction to go to these hospitals if they have mazor robotics? >> i think we can see it in many dpim different places around the country where hospitals really

promote and market the technology. and they have clinical data to show the effectiveness of this technology, and indeed you're right, a lot of these hospitals buy and then promote and this has become a positional element in market -- and they benefit -- operated with our technology. >> medtronic is a big company, they can choose to partner with any of them, why did they partner with you? >> so, yeah, as you can imagine, there's a lot of excitement today around robotics in the spine surgery, and being the leader in this area, we had the privilege, i would say, to be very selective, we can work with any company, i believe in the spine surgery and many of them were interested. and because of this position, we are not surprisingly choose to work with medtronic, and they

are the leader in spine, and there is a great deal of synergy between the companies, it's not only that we are the leaders in spine robotics, we share a lot of things in the culture, in the mission, in looking at the fashlt thenlss, and this, the ability to have access to work together, with such a giant player in the spine, having access to all the big academic centers, hospitals around the world, both in the u.s. and out of the u.s. is something that is part of our growth strategy. and this was part of our strategy to accelerate our growth, now when we introduce the -- >> let's say this blows out the sales and people catch on like they did with intuitive surgi l surgical. are you able to make enough to meet demand? >> i think so, i don't think we have any limitation on the ability to manufacture units and

i feel very comfortable with our ability to deliver the units to the market and we are training and hiring the team in order to support the cases and we're looking for the future, i think we have a huge market with great opportunities and we are really happy with this market we're sharing with medtronics. >> i think this does feel very much like intuitive surgical. and a lot of people said no one's going to use it. but it's turned out to be a draw for hospitals who have it. the ceo of mazor robotics, thanks for coming on the show. "mad money's" back after this. think again.

this is the new new york. we are building new airports all across the state. new roads and bridges. new mass transit. new business friendly environment. new lower taxes. and new university partnerships to grow the businesses of tomorrow today. learn more at esd.ny.gov it's your tv, take it with you. with directv now and at&t, get the ultimate in entertainment plus unlimited data. get directv now for $10 a month when you have the new at&t unlimited plus plan.

it is time, it's time for "the lightning round". [ buzzer ] >> and then the lightning round

is over. are you ready, skee-daddy. we'll start with jovan any in new york. jovans c jovani. >> caller: by, sell or hold, ntnx. >> nutanix, going to go to stso. let's go to noah in california. >> caller: i just had a quick question, going through earnings season here, what is your take on jet blue? >> if we're going to go to the airlines, it's going to be southwest air, with travel trust edition club knows that, and after that it going to be alaska, then it's going to be delta. we're not going to go down to jetblue, it's had a good run, but we're not going to invest in

jetblue. >> caller: i'm talking about prlb, i'm wondering what your thoughts are. >> i got to do work, when it comes to injection electronics, i don't have the answer to that. let's go to steve in virginia. >> caller: my question is about mondelez, my question is where in your opinion is this company going? >> i am going to tell you to hold it because i think there's great value will. i think they are in the last year of a turn around. therefore you have to own it. it's a stable, good grower, not great. so my answer is it could creep up over time, it's not going to

be an overnight success, it's going to increase, unless they put the company up over time. bruce in mississippi. >> caller: i'm blessed to be here, sunny mississippi. i understand they're having positive clinical results in treating epilepsy and tourette's syndrome, i'm invested in a few of the companies. >> this is a speculative one, gw pharma, legalization nationwide is going to hurt both companies, that is the end of the lightning round. >> t h the dog-sized horse? i'm crazy stressed trying to figure out this complex trade

so i brought in my comfort pony, warren, to help me deal. isn't that right warren? well, you could get support from thinkorswim's in-app chat. it lets you chat and share your screen directly with a live person right from the app, so you don't need a comfort pony. oh, so what about my motivational meerkat? in-app chat on thinkorswim. only at td ameritrade.

does it matter if this british election occurs with a snap? do we need to be worried about the german elections come the fall? if you're a hedge fund manager, absolutely you do need to worry. if you're a bond fund manager,

definitely. fund managers have to worry about short-term gains. but if you're an individual investor, it's a different story, you can be aware of european moll ticks, but i hesitate to do more than that, because i'm afraid you'll take action. and it will be detrimental too your portfolio. i think we have been stuck in a rough one when it comes to europe. the markets initial reaction to brexit and the shocking declines it caused around the globe, including here. but to me, that's learning the wrong lesson, when you consider the sharp rebound in u.s. stock after the june 23 brexit stocker, you'll realize how totally hedge fund the brexit was. let's look back at what happened after brexit. the dow dropped from 18,078 to 17,063 in two days, then over the next three days it came back, and then it was up 500

points. yet it's that same volatility that the hedge funds search for to make great money. in retrospect, it meant very little, except as a panic, the panic to give you a great place to buy, when you have nonsystemic risk, that's not even in our country, any panic selloff tends to be a buying opportunity. hedge funds have an insane drive to trade something, anything, particularly to the down side, they love and lust for volatility, because it creates trading opportunities. a hedge fund perspective, it ends up a whole rational discourse, the vast majority of you are not hedge fund managers. i'm not saying that the first round of the french presidential election coming this sunday doesn't matter, if you're french, obviously it matters.

right now the french election seems to be a four-way race, wall street regards two of these candidates, one on the far left and one on the far right scary, just scary. the hard leftist wins, you probably don't want to invest in brench businesses because of the tax considerations or french bonds. the prospect that this guy might win is a major reason why french bonds have been selling off, why people from europe keep investing in safer u.s. treasuries, on the other hand if marine le pen makes it to the second round and wins the election, she said she would take france off of eu. but if you live in america, the result is really the same, higher u.s. bond prices, lower interest rates. if you are concerned about stocks because of european elections, you need to focus on that quick down after the brexit elections, selling, because of european politics has been a

mistake endlessly. given how the all powerful al gore al gogorithalgorithms, int also go down and that does trigger s&p 500 selling, but i say ignore that ridiculous bond stock inkage and buy stocks of high quality companies that get knocked down because of these elections. or be prepared to buy an indexed fund. learn it, know it, be ready when the event happened. remember, no one has ever made a dime panicking, but make loads of money when staying on the other side of the panicking. stay with cramer.

america, excess, qualcomm, nod bad for an evening. i'm jim cramer, and i will see you tomorrow.

okay, let's go. find your awesome with the xfinity x1 voice remote. that's amazing! >> welcome to the shark tank, where entrepreneurs seeking an investment will face these sharks. if they hear a great idea, they'll invest their own money or fight each other for a deal. this is "shark tank." ♪ my name is tony devine, and i'm from bristol, pennsylvania. my product is going to revolutionize the way we train for basketball. finish! finish! oh, let's go. use that left hand! i've been a basketball coach my entire life... let's go! and i always felt like there was something missing, and that was the realism when you practiced.